You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 13, Issue 15

August-1 2021 - 276 articles

Cover Story: Giant cell tumor of bone is a primary bone tumor of intermediate malignancy. Since the United States Food and Drug Administration approved the use of denosumab for giant cell tumors of bone in 2013, the treatment strategy for giant cell tumors of bone has changed significantly. Denosumab can stop the growth of unresectable lesions and relieve pain. Preoperative administration of denosumab reduces extraosseous lesions, hardens the tumor, and facilitates en bloc resection. On the other hand, administration of denosumab before curettage makes curettage difficult due to osteosclerosis of the lesion. We review the literature on the treatment of giant cell tumors of bone and consider the treatment strategy for giant cell tumors of bone in the denosumab era. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (276)

  • Article
  • Open Access
9 Citations
4,245 Views
15 Pages

Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer

  • Inga Nazarova,
  • Maria Slyusarenko,
  • Elena Sidina,
  • Nadezhda Nikiforova,
  • Vladislav Semiglazov,
  • Tatiana Semiglazova,
  • Achim Aigner,
  • Evgeny Rybakov and
  • Anastasia Malek

3 August 2021

Purpose: Developing new and efficient approaches for the early diagnosis of colorectal cancer (CRC) is an important issue. Circulating extracellular nanovesicles (ENVs) present a promising class of cancer markers. Cells of well-differentiated adenoca...

  • Article
  • Open Access
18 Citations
6,541 Views
21 Pages

Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells

  • Jaya Padmanabhan,
  • Biswarup Saha,
  • Chase Powell,
  • Qianxing Mo,
  • Bradford A. Perez and
  • Srikumar Chellappan

3 August 2021

Non-small cell lung cancer has a 5-year survival rate of less than 12–15%, calling for the development of additional therapeutic strategies to combat this disease. Here we tested the efficacy of inhibiting cyclin-dependent kinase 9 (CDK9) on lung can...

  • Article
  • Open Access
9 Citations
3,538 Views
18 Pages

Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma

  • Stefanie Meyer,
  • Diana Handke,
  • Anja Mueller,
  • Katharina Biehl,
  • Markus Kreuz,
  • Jürgen Bukur,
  • Ulrike Koehl,
  • Maria-Filothei Lazaridou,
  • Mark Berneburg and
  • André Steven
  • + 2 authors

3 August 2021

Background: The human leukocyte antigen (HLA) class II molecules are constitutively expressed in some melanoma, but the underlying molecular mechanisms have not yet been characterized. Methods: The expression of HLA class II antigen processing machin...

  • Review
  • Open Access
40 Citations
7,526 Views
26 Pages

MicroRNA and Other Non-Coding RNAs in Epstein–Barr Virus-Associated Cancers

  • Kin Israel Notarte,
  • Suranga Senanayake,
  • Imee Macaranas,
  • Pia Marie Albano,
  • Lucia Mundo,
  • Eanna Fennell,
  • Lorenzo Leoncini and
  • Paul Murray

3 August 2021

EBV is a direct causative agent in around 1.5% of all cancers. The oncogenic properties of EBV are related to its ability to activate processes needed for cellular proliferation, survival, migration, and immune evasion. The EBV latency program is req...

  • Article
  • Open Access
6 Citations
3,195 Views
18 Pages

Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas

  • Ramesh Paudyal,
  • Milan Grkovski,
  • Jung Hun Oh,
  • Heiko Schöder,
  • David Aramburu Nunez,
  • Vaios Hatzoglou,
  • Joseph O. Deasy,
  • John L. Humm,
  • Nancy Y. Lee and
  • Amita Shukla-Dave

3 August 2021

The present study aimed to investigate the correlation at pre-treatment (TX) between quantitative metrics derived from multimodality imaging (MMI), including 18F-FDG-PET/CT, 18F-FMISO-PET/CT, DW- and DCE-MRI, using a community detection algorithm (CD...

  • Review
  • Open Access
48 Citations
13,626 Views
20 Pages

An Overview on the Histogenesis and Morphogenesis of Salivary Gland Neoplasms and Evolving Diagnostic Approaches

  • Janaki Iyer,
  • Arvind Hariharan,
  • Uyen Minh Nha Cao,
  • Crystal To Tam Mai,
  • Athena Wang,
  • Parisa Khayambashi,
  • Bich Hong Nguyen,
  • Lydia Safi and
  • Simon D. Tran

3 August 2021

Salivary gland neoplasms (SGN) remain a diagnostic dilemma due to their heterogenic complex behavior. Their diverse histomorphological appearance is attributed to the underlying cellular mechanisms and differentiation into various histopathological s...

  • Article
  • Open Access
15 Citations
8,138 Views
17 Pages

3 August 2021

Background: Radiation-associated angiosarcoma of the breast (RAASB) is a rare, challenging disease, with surgery being the accepted basic therapeutic approach. In contrast, the role of adjuvant and systemic therapies is a subject of some controversy....

  • Article
  • Open Access
8 Citations
2,793 Views
12 Pages

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma

  • Sofie H. Tolmeijer,
  • Rutger H. T. Koornstra,
  • Jan Willem B. de Groot,
  • Maartje J. Geerlings,
  • Dirk H. van Rens,
  • Marye J. Boers-Sonderen,
  • Jack A. Schalken,
  • Winald R. Gerritsen,
  • Marjolijn J. L. Ligtenberg and
  • Niven Mehra

3 August 2021

For patients with newly diagnosed metastatic melanoma, rapid BRAF mutation (mBRAF) assessment is vital to promptly initiate systemic therapy. Additionally, blood-based biomarkers are desired to monitor and predict treatment response. Circulating tumo...

  • Article
  • Open Access
16 Citations
4,036 Views
17 Pages

Consistency of Pituitary Adenoma: Prediction by Pharmacokinetic Dynamic Contrast-Enhanced MRI and Comparison with Histologic Collagen Content

  • Kiyohisa Kamimura,
  • Masanori Nakajo,
  • Manisha Bohara,
  • Daigo Nagano,
  • Yoshihiko Fukukura,
  • Shingo Fujio,
  • Tomoko Takajo,
  • Kazuhiro Tabata,
  • Takashi Iwanaga and
  • Hiroshi Imai
  • + 2 authors

3 August 2021

Prediction of tumor consistency is valuable for planning transsphenoidal surgery for pituitary adenoma. A prospective study was conducted involving 49 participants with pituitary adenoma to determine whether quantitative pharmacokinetic analysis of d...

  • Article
  • Open Access
2 Citations
3,586 Views
9 Pages

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel

  • Leni van Doorn,
  • Mandy M. van Rosmalen,
  • Wendy M. van der Deure,
  • Esther Oomen-de Hoop,
  • Robert Porrazzo,
  • Sophie M. Wijngaard,
  • Ingrid A. Boere,
  • Paola Veenstra,
  • Eman Ibrahim and
  • Peter de Bruijn
  • + 4 authors

3 August 2021

Chemotherapy-induced alopecia (CIA), a side effect with high impact, can be prevented by cooling the scalp during the administration of some cytotoxic drugs. However, the effects of this prolonged scalp cooling on the pharmacokinetics of chemotherapy...

of 28

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694